Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Diversity of Antigen Receptors

Diversity of Antigen Receptors

Antigen receptors are essential components of the immune system crucial in defending the body against foreign invaders. These receptors are present on the surface of B and T cells, enabling them to recognize antigens and mount an appropriate immune response.
Before encountering any antigen, lymphocytes express these receptors. On B cells, the antigen receptor is a membrane-bound antibody molecule called BCR; on T cells, it is a T cell receptor or TCR. B and T cell receptors are composed of two...

T Cell Activation and Clonal Selection

T Cell Activation and Clonal Selection

T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Neoadjuvant Nivolumab with or without Ipilimumab for Cisplatin-Ineligible Patients with Muscle-Invasive Bladder Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Same author

Determinants of sensitivity to HER2-targeted antibody drug conjugates in urothelial cancer.

Nature communications·2025

Same author

IK-175, an Oral Aryl Hydrocarbon Receptor Inhibitor, Alone and with Nivolumab in Patients with Advanced Solid Tumors and Urothelial Carcinoma.

Clinical cancer research : an official journal of the American Association for Cancer Research·2025

Same author

ABBV-303 Is an NK-cell Engager Specific for c-Met-Expressing Tumors.

Cancer research·2025

Same author

End Points for the Next-Generation Bladder-Sparing Perioperative Trials for Patients With Muscle-Invasive Bladder Cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2025

Same author

Combinability of epcoritamab CD20-targeting T-cell engager and CD20 antibody-targeted therapies in B-cell non-Hodgkin lymphoma.

Leukemia & lymphoma·2025

Search research articles

Related Experiment Video

Updated: May 26, 2026

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Published on: May 9, 2025

T cell receptor engineering.

Jennifer D Stone¹, Adam S Chervin, David H Aggen

¹Department of Biochemistry, University of Illinois, Urbana, Illinois, USA.

Methods in Enzymology

|January 11, 2012

Summary

This summary is machine-generated.

Researchers engineered T cell receptors (TCRs) to target cancer and viral infections. Methods include yeast display, T cell display, and E. coli expression for enhanced TCR therapies.

More Related Videos

Generating De Novo Antigen-specific Human T Cell Receptors by Retroviral Transduction of Centric Hemichain

Generating De Novo Antigen-specific Human T Cell Receptors by Retroviral Transduction of Centric Hemichain

Published on: October 25, 2016

Retroviral Transduction of T-cell Receptors in Mouse T-cells

Retroviral Transduction of T-cell Receptors in Mouse T-cells

Published on: October 22, 2010

Related Experiment Videos

Last Updated: May 26, 2026

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Published on: May 9, 2025

Generating De Novo Antigen-specific Human T Cell Receptors by Retroviral Transduction of Centric Hemichain

Generating De Novo Antigen-specific Human T Cell Receptors by Retroviral Transduction of Centric Hemichain

Published on: October 25, 2016

Retroviral Transduction of T-cell Receptors in Mouse T-cells

Retroviral Transduction of T-cell Receptors in Mouse T-cells

Published on: October 22, 2010

Area of Science:

Immunology
Molecular Biology
Biotechnology

Background:

T lymphocytes utilize T cell receptors (TCRs) to recognize foreign antigens presented as peptide/MHC complexes.
TCRs can target intracellular proteins, offering a broader antigen recognition spectrum than antibodies.
Significant advancements in engineering TCRs aim to improve cancer and viral infection therapies.

Purpose of the Study:

To describe methods for engineering T cell receptors (TCRs) with enhanced affinity and therapeutic potential.
To explore novel strategies for developing TCR-based immunotherapies.

Main Methods:

Engineering higher-affinity single-chain VαVβ TCRs (scTv) using a yeast display system.
Developing higher-affinity full-length TCRs through a T cell display system.
Expressing, purifying, and characterizing soluble TCRs utilizing an Escherichia coli system.

Main Results:

Demonstrated feasibility of engineering TCRs with improved affinity for therapeutic applications.
Established multiple platforms for TCR engineering and characterization.
Provided a foundation for developing novel TCR-based cancer and antiviral treatments.

Conclusions:

Engineered TCRs hold significant promise for targeted cancer and viral therapies.
The described methods offer versatile approaches for TCR engineering and development.
Further research in TCR engineering will advance adoptive T cell therapies.